Corrigendum to “Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis” [Anal. Biochem. 416 (2011) 206–210] (**** (2011) 416(2) (206–210), (S000326971100337X), (10.1016/j.ab.2011.05.029));Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis

Analytical Biochemistry

Volumn 416, Issue 2, 2011, Pages 206-210

  Copeland, Robert A ^a   Basavapathruni, Aravind ^a   Moyer, Mikel ^a   Scott, Margaret Porter ^a  

^a EPIZYME INC   (United States)

Author keywords

Drug discovery; Drug target residence time; Jump dilution analysis; Tight binding inhibition

Indexed keywords

DILUTION; DISSOCIATION; RECOVERY;

ACTIVITY RECOVERY; DILUTION ANALYSIS; DISSOCIATION RATES; DRUG DISCOVERY; ENZYME CONCENTRATIONS; IRREVERSIBLE INHIBITIONS; RESIDENCE TIME; TIGHT BINDING;

ENZYME INHIBITION;

DIMETHYL SULFOXIDE; ENZYME INHIBITOR; ENZYME;

CONTROLLED STUDY; DILUTION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; JUMP DILUTION ANALYSIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SHORT SURVEY; SIMULATION; STOICHIOMETRY; ARTICLE; CHEMISTRY; KINETICS; METABOLISM; PROTEIN BINDING; TIME;

ENZYME INHIBITORS; ENZYMES; KINETICS; PROTEIN BINDING; TIME FACTORS;

EID: 80155199028     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2022.114637     Document Type: Erratum

References (15)

1. J.F. Morrison, C.T. Walsh, The behavior and significance of slow-binding enzyme inhibitors, Adv. Enzymol. 61 (1988) 201-301.
2. R.A. Copeland, Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists, John Wiley, Hoboken, NJ, 2005.
3. R.A. Copeland, D.L. Pompliano, T.D. Meek, Drug-target residence time and its implications for lead optimization, Nat. Rev. Drug Discov. 5 (2006) 730-739. (Pubitemid 44323700)
4. K. Babaoglu, A. Simeonov, J.J. Irwin, M.E. Nelson, B. Feng, C.J. Thomas, L. Cancian, M.P. Costi, D.A. Maltby, A. Jadhav, J. Inglese, C.P. Austin, B.K. Shoichet, Comprehensive mechanistic analysis of hits from high-throughput and docking screens against b-lactamase, J. Med. Chem. 51 (2008) 2502-2511. (Pubitemid 351628511)
5. R.A. Copeland, Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, John Wiley, New York, 2000.
6. P.J. Tummino, R.A. Copeland, Residence time of receptor-ligand complexes and its effect on biological function, Biochemistry 47 (2008) 5481-5492. (Pubitemid 351711169)
7. R.A. Copeland, The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety, Expert Opin. Drug Discov. 5 (2010) 305-310.
8. G. Vauquelin, I. Van Liefde, Slow antagonist dissociation and long-lasting in vivo receptor protection, Trends Pharmacol. Sci. 27 (2006) 355-359. (Pubitemid 43963183)
9. R. Zhang, F. Monsma, The importance of drug-target residence time, Curr. Opin. Drug Discov. Dev. 12 (2009) 488-496.
10. J. Gabrielsson, H. Dolgos, P-G. Gillberg, U. Bredberg, B. Benthem, G. Duker, Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations, Drug Discov. Today 14 (2009) 358-372.
11. H.J. Motulsky, L.C. Mahan, The kinetics of competitive radioligand binding predicted by the law of mass action, Mol. Pharmacol. 25 (1984) 1-9. (Pubitemid 14223246)
12. K. Yan, L. Madden, A.E. Choudhry, C.S. Voigt, R.A. Copeland, R.R. Gontarek, Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes, Antimicrob. Agents Chemother. 50 (2006) 3875-3881. (Pubitemid 44684906)
13. M.A. Cooper, Optical biosensors in drug discovery, Nat. Rev. Drug Discov. 1 (2002) 515-528. (Pubitemid 37368826)
14. J.B. Chaires, Calorimetry and thermodynamics in drug design, Annu. Rev. Biophys. 37 (2008) 135-151.
15. U.H. Danielson, Integrating surface plasmon resonance biosensor-based interaction kinetic analysis into the lead discovery and optimization process, Future Med. Chem. 1 (2009) 1399-1414.